Glucocorticoid-induced osteoporosis: management update

Area of Science:

• Endocrinology
• Rheumatology
• Pharmacology

Background:

• Glucocorticoid-induced osteoporosis (GIOP) remains a significant clinical challenge in managing inflammatory disorders.
• Despite existing guidelines, patient attention to fracture risk associated with GIOP is often insufficient.
• New therapeutic agents offer potential improvements in GIOP management.

Purpose of the Study:

• To discuss novel treatments for GIOP that may enhance patient management.
• To review the efficacy and safety of emerging therapies for glucocorticoid-induced osteoporosis.

Main Methods:

• Review of current literature on treatments for GIOP.
• Discussion of FDA-approved agents: intravenous zoledronic acid (ZA) and teriparatide (TPT).
• Consideration of denosumab as a potential future treatment option.

Main Results:

• Zoledronic acid (ZA), an antiresorptive agent, offers a convenient annual infusion for GIOP treatment.
• Teriparatide (TPT), an osteoblast stimulator, addresses the pathophysiology of GIOP by enhancing bone formation.
• Denosumab shows potential as an antiresorptive agent, pending FDA approval.

Conclusions:

• New treatments like ZA and TPT are poised to improve the management of GIOP.
• These agents offer distinct mechanisms of action to combat bone loss in GIOP patients.
• Further research and FDA approval of agents like denosumab may expand therapeutic options for GIOP.